Agilent’s Ki-67 IHC MIB-1 pharmDx gets FDA approval as an aid in identifying patients with early breast cancer at high risk of disease recurrence.
- First IHC assay measuring Ki-67 expression to receive FDA approval in the context of treatment with Verzenio and was developed in collaboration with Eli Lilly
- “Its approval establishes a clinically relevant standard for recurrence risk assessment in EBC so that more high-risk patients who may experience clinical benefit from treatment with Verzenio are identified,” said Sam Raha, president of Agilent’s Diagnostics and Genomics Group
- Co. shares up 1% post-market
To view the source of this information, …